6Toyota T,Hirata Y,Ikeda Y,et al.Lipo-PGE1,a new lipid encapsulated preparation of prostaglandin E1:placeboo and prostaglandin E1 controlled multicenter trials in patients with dinbetic neuropathy and leg ulcers[J].Prostaglandins.1993,46:453-468.
2Cawello W,Leonhardt A,Schweer H,etal.Dose proportional pharmacokinetics of alpro-stadil （prostaglandin E1）in healthyvolunteers following intravenous infusion 〔J〕.Br J Clin Pharmacol,1995,40：273～276.
3Anggard E.The biological activities of three metabolites of prostaglandin E1 〔J〕.ActaPhysiol Scand,1996,66：509～510.
4Yasuda H,Maeda K,Sonobe M,et al.Metabolic effect of PGE1 analogue O1206.αCD onnerve Na＋-K＋-ATPase activity of rats with streptozotocin-induced diabetes is mediatedvia cAMP: possible role of cAMP in diabetic neuropathy 〔J〕.Prostaglandins,1994,47：367～378.
5Okada S,Ichiki K,Tanokuchi S,et al.Effect of prostaglandin E1 on therenin-aldosterone system in patients with diabetic nephropathy 〔J〕.J Int MedRes,1993,21：126～132.
6Young MJ, Veves A,Smith JV, et al.Restoring lower limb blood flow improvesconduction velocity in diabetic patients 〔J〕.Diabetologia,1995,38：1051～1054.
7Partanen J,Niskanen L,Lehtinen J,et al.Natural history of peripheral neuropathy inpatients with non-insulin-dependent diabetes mellitus 〔J〕. N Engl J Med,1995,333：89～94.
8Yasuda H,Sonobe M,Hatanaka I,et al.A new prostaglandin E1 analogue （TFC-612）prevents a decrease in motor conduction velocity in streptozocin-diabetic rats 〔J〕.BiochemBiophys Res Commun,1998,150：225～230.
9Shindo H,Tawata M,Inoue M,et al.The effect of prostaglandin E1.αCD on vibratorythreshold determined with the SMV-5 vibrometer in patients with diabetic neuropathy 〔J〕.DiabetesRes Clin Pract,1994,24：173～180.
10Okada S,Sato K,Higuchi T,et al.Influence of prostaglandin E1 on slight proteinuriain non-azotaemic diabetes 〔J〕.J Int Med Res,1992,20：94～97.
